MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/425/0.01/20.12.24 | Delayed Börse Stuttgart 15:49:11 04/07/2024 BST | ||
| 0.68 EUR | 0.00% |
|
| Current month | -5.56% | ||
| 1 month | -2.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/07/24 | 0.68 | 0.00% |
| 03/07/24 | 0.68 | -6.85% |
| 02/07/24 | 0.73 | +4.29% |
| 01/07/24 | 0.7 | -2.78% |
| 28/06/24 | 0.72 | -1.37% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 03:49 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME662X |
| ISIN | DE000ME662X0 |
| Date issued | 02/01/2024 |
| Strike | 425 $ |
| Maturity | 20/12/2024 (169 Days) |
| Parity | 100 : 1 |
| Emission price | 0.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.84 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.02 € |
| Spread % | 2.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
